Cargando…

High EASIX score is an independent predictor of non-relapse mortality in patients with CMML undergoing allogeneic stem cell transplant

Detalles Bibliográficos
Autores principales:	Baranwal, Anmol, Mangaonkar, Abhishek, Shah, Mithun V., Litzow, Mark R., Hogan, William J., Patnaik, Mrinal M., Alkhateeb, Hassan B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9715426/ https://www.ncbi.nlm.nih.gov/pubmed/36131003 http://dx.doi.org/10.1038/s41409-022-01829-w

Ejemplares similares

P1323: PREDICTION OF NON-RELAPSE MORTALITY BY EASIX AND HCT-CI SCORES IN PATIENTS WITH CHRONIC MYELOMONOCYTIC LEUKEMIA UNDERGOING ALLOGENEIC STEM CELL TRANSPLANT
por: Baranwal, A., et al.
Publicado: (2022)

Outcomes of allogeneic transplant in patients with DDX41 mutated myelodysplastic syndrome and acute myeloid leukemia
por: Baranwal, Anmol, et al.
Publicado: (2022)

CSF3R T618I mutant chronic myelomonocytic leukemia (CMML) defines a proliferative CMML subtype enriched in ASXL1 mutations with adverse outcomes
por: Bezerra, Evandro D., et al.
Publicado: (2021)

Prognostic impact and timing considerations for allogeneic hematopoietic stem cell transplantation in chronic myelomonocytic leukemia
por: Pophali, Prateek, et al.
Publicado: (2020)

Salvage use of venetoclax-based therapy for relapsed AML post allogeneic hematopoietic cell transplantation
por: Joshi, Maansi, et al.
Publicado: (2021)

Abnormal karyotype is an independent predictor of inferior survival in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
por: Abdallah, Mostafa, et al.
Publicado: (2023)

Molecular predictors of response to venetoclax plus hypomethylating agent in treatment-naïve acute myeloid leukemia
por: Gangat, Naseema, et al.
Publicado: (2022)

Characteristics and outcomes of therapy-related myeloid neoplasms following autologous stem cell transplantation for multiple myeloma
por: Nadiminti, Kalyan, et al.
Publicado: (2021)

P580: CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH WT1 MUTATED MYELOID NEOPLASMS: MAYO CLINIC EXPERIENCE
por: Basmaci, Rami, et al.
Publicado: (2023)

Immune-Mediated Autonomic Neuropathies following Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia
por: Mangaonkar, Abhishek, et al.
Publicado: (2017)

Observation and treatment in DDX41-mutated acute myeloid leukemia and myelodysplastic syndrome
por: Al-Kali, Aref, et al.
Publicado: (2023)

CPX-351 (Vyxeos™) treatment in blast-phase myeloproliferative neoplasm (MPN-BP): real-world experience in 12 consecutive cases
por: Ilyas, Rimal, et al.
Publicado: (2023)

Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions
por: Valent, Peter, et al.
Publicado: (2019)

EASIX, Modified EASIX and Simplified EASIX as an Early Predictor for Intensive Care Unit Admission and Mortality in Severe COVID-19 Patients
por: Zińczuk, Aleksander, et al.
Publicado: (2022)

P1346: THE IMPACT OF CYTOTOXIC THERAPY ON THE RISK OF PROGRESSION AND DEATH IN PATIENTS WITH CLONAL CYTOPENIA OF UNDETERMINED SIGNIFICANCE.
por: Marissa, LI, et al.
Publicado: (2023)

Prognostic interaction between bone marrow morphology and SF3B1 and ASXL1 mutations in myelodysplastic syndromes with ring sideroblasts
por: Mangaonkar, Abhishek A., et al.
Publicado: (2018)

Pre-transplant EASIX and sepsis after allogeneic stem cell transplantation
por: Korell, Felix, et al.
Publicado: (2022)

Clinical outcome of myelodysplastic syndrome progressing on hypomethylating agents with evolving frontline therapies: continued challenges and unmet needs
por: Ghorab, Ahmad, et al.
Publicado: (2022)

Clinical and biological characteristics and prognostic impact of somatic GATA2 mutations in myeloid malignancies: a single institution experience
por: Nanaa, Ahmad, et al.
Publicado: (2021)

EASIX-1year and late mortality after allogeneic stem cell transplantation
por: Kordelas, Lambros, et al.
Publicado: (2023)

Infrequent occurrence of TET1, TET3, and ASXL2 mutations in myelodysplastic/myeloproliferative neoplasms
por: Lasho, Terra L., et al.
Publicado: (2018)

A population-based study of chronic neutrophilic leukemia in the United States
por: Ruan, Gordon J., et al.
Publicado: (2020)

Outcome of patients with acute myeloid leukemia following failure of frontline venetoclax plus hypomethylating agent therapy
por: Gangat, Naseema, et al.
Publicado: (2023)

Prognostic value of CPSS cytogenetic risk classification in patients with CMML after allogeneic hematopoietic cell transplantation: a retrospective multicenter study of the Chronic Malignancies Working Party of the EBMT
por: Koenecke, Christian, et al.
Publicado: (2022)

Predictors of response to venetoclax plus hypomethylating agent therapy and survival in blast-phase myeloproliferative neoplasm
por: Gangat, Naseema, et al.
Publicado: (2022)

A novel Iowa–Mayo validated composite risk assessment tool for allogeneic stem cell transplantation survival outcome prediction
por: Nadiminti, Kalyan, et al.
Publicado: (2021)

Treatment outcome of clonal cytopenias of undetermined significance: a single-institution retrospective study
por: Xie, Zhuoer, et al.
Publicado: (2021)

ASXL1 frameshift mutations drive inferior outcomes in CMML without negative impact in MDS
por: Sallman, David A, et al.
Publicado: (2017)

Validation of pre-conditioning EASIX for prediction of sepsis after allogeneic stem cell transplantation
por: Korell, Felix, et al.
Publicado: (2023)

P1374: EASIX ASSESSED AT 1 YEAR AFTER ALLOGENIC HEMATOPOIETIC CELL TRANSPLANTATION PREDICTS THE ONSET OF SUBSEQUENT NON-RELAPSE MORTALITY
por: Takeda, R., et al.
Publicado: (2022)

Black African-American patients with primary myelofibrosis: a comparative analysis of phenotype and survival
por: Gangat, Naseema, et al.
Publicado: (2023)

Mouse Models of CMML
por: Belotserkovskaya, Ekaterina, et al.
Publicado: (2021)

Predicting sinusoidal obstruction syndrome after allogeneic stem cell transplantation with the EASIX biomarker panel
por: Jiang, Sihe, et al.
Publicado: (2020)

Dynamic EASIX scores closely predict nonrelapse mortality after allogeneic hematopoietic cell transplantation
por: Nawas, Mariam T., et al.
Publicado: (2022)

Daunorubicin-60 versus daunorubicin-90 versus idarubicin-12 for induction chemotherapy in acute myeloid leukemia: a retrospective analysis of the Mayo Clinic experience
por: Tefferi, Ayalew, et al.
Publicado: (2022)

Core-binding factor acute myeloid leukemia: long-term outcome of 70 patients uniformly treated with “7+3”
por: Begna, K. H., et al.
Publicado: (2022)

Practical limitations of monocyte subset repartitioning by multiparametric flow cytometry in chronic myelomonocytic leukemia
por: Pophali, Prateek A., et al.
Publicado: (2019)

Clonal Hematopoiesis and Myeloid Neoplasms in the Context of Telomere Biology Disorders
por: Ferrer, Alejandro, et al.
Publicado: (2022)

Therapy-related clonal cytopenia as a precursor to therapy-related myeloid neoplasms
por: Shah, Mithun Vinod, et al.
Publicado: (2022)

P734: CLONAL HEIRARCHY AND HETEROGENEITY IN STAG2M MYELOID NEOPLASMS: THE MAYO CLINIC EXPERIENCE
por: Katamesh, Bahga, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_1ph96jv2sm7kbmc7j249v9o84i